Molecular Signatures of Cutaneous Dupilumab Response — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Molecular Signatures of Cutaneous Dupilumab Response — Stella

Recruiting

Back to Atopic Dermatitis trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

University of California, San Francisco, San Francisco, California

Key details

Phase

Post-approval study

Sponsor

University of California, San Francisco

Enrollment target

~15 participants

Started

February 2023

Primary completion

February 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov